These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
420 related articles for article (PubMed ID: 19649205)
1. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo. Chen Z; Lin Y; Barbieri E; Burlingame S; Hicks J; Ludwig A; Shohet JM Neoplasia; 2009 Aug; 11(8):753-62. PubMed ID: 19649205 [TBL] [Abstract][Full Text] [Related]
2. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells. Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562 [TBL] [Abstract][Full Text] [Related]
3. Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma. He J; Gu L; Zhang H; Zhou M Cell Cycle; 2011 Sep; 10(17):2994-3002. PubMed ID: 21862876 [TBL] [Abstract][Full Text] [Related]
4. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63. Gamble LD; Kees UR; Tweddle DA; Lunec J Oncogene; 2012 Feb; 31(6):752-63. PubMed ID: 21725357 [TBL] [Abstract][Full Text] [Related]
5. MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis. Slack A; Lozano G; Shohet JM Cancer Lett; 2005 Oct; 228(1-2):21-7. PubMed ID: 15927364 [TBL] [Abstract][Full Text] [Related]
6. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Slack A; Chen Z; Tonelli R; Pule M; Hunt L; Pession A; Shohet JM Proc Natl Acad Sci U S A; 2005 Jan; 102(3):731-6. PubMed ID: 15644444 [TBL] [Abstract][Full Text] [Related]
7. MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells. Gu L; Zhang H; He J; Li J; Huang M; Zhou M Oncogene; 2012 Mar; 31(11):1342-53. PubMed ID: 21822304 [TBL] [Abstract][Full Text] [Related]
8. MDM2 as a critical effector of the MYCN oncogene in tumorigenesis. Slack A; Shohet JM Cell Cycle; 2005 Jul; 4(7):857-60. PubMed ID: 15917661 [TBL] [Abstract][Full Text] [Related]
9. p53 is a direct transcriptional target of MYCN in neuroblastoma. Chen L; Iraci N; Gherardi S; Gamble LD; Wood KM; Perini G; Lunec J; Tweddle DA Cancer Res; 2010 Feb; 70(4):1377-88. PubMed ID: 20145147 [TBL] [Abstract][Full Text] [Related]
10. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722 [TBL] [Abstract][Full Text] [Related]
11. Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression. Carr-Wilkinson J; Griffiths R; Elston R; Gamble LD; Goranov B; Redfern CP; Lunec J; Tweddle DA Cell Cycle; 2011 Nov; 10(21):3778-87. PubMed ID: 22052359 [TBL] [Abstract][Full Text] [Related]
12. miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs. Terrile M; Bryan K; Vaughan L; Hallsworth A; Webber H; Chesler L; Stallings RL PLoS One; 2011; 6(12):e28356. PubMed ID: 22164278 [TBL] [Abstract][Full Text] [Related]
13. Novel anthranilamide-pyrazolo[1,5-a]pyrimidine conjugates modulate the expression of p53-MYCN associated micro RNAs in neuroblastoma cells and cause cell cycle arrest and apoptosis. Ramaiah MJ; Pushpavalli SN; Lavanya A; Bhadra K; Haritha V; Patel N; Tamboli JR; Kamal A; Bhadra U; Pal-Bhadra M Bioorg Med Chem Lett; 2013 Oct; 23(20):5699-706. PubMed ID: 23992861 [TBL] [Abstract][Full Text] [Related]
14. Oncolytic adenovirus armed with shRNA targeting MYCN gene inhibits neuroblastoma cell proliferation and in vivo xenograft tumor growth. Li Y; Zhang B; Zhang H; Zhu X; Feng D; Zhang D; Zhuo B; Li L; Zheng J J Cancer Res Clin Oncol; 2013 Jun; 139(6):933-41. PubMed ID: 23443256 [TBL] [Abstract][Full Text] [Related]
15. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma. Regan PL; Jacobs J; Wang G; Torres J; Edo R; Friedmann J; Tang XX Int J Oncol; 2011 Jan; 38(1):105-12. PubMed ID: 21109931 [TBL] [Abstract][Full Text] [Related]
16. MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response. Petroni M; Veschi V; Prodosmo A; Rinaldo C; Massimi I; Carbonari M; Dominici C; McDowell HP; Rinaldi C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Soddu S; Giannini G Mol Cancer Res; 2011 Jan; 9(1):67-77. PubMed ID: 21173028 [TBL] [Abstract][Full Text] [Related]
17. The interaction between FAK, MYCN, p53 and Mdm2 in neuroblastoma. Waters AM; Beierle EA Anticancer Agents Med Chem; 2014 Jan; 14(1):46-51. PubMed ID: 24041229 [TBL] [Abstract][Full Text] [Related]
18. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Chesler L; Goldenberg DD; Collins R; Grimmer M; Kim GE; Tihan T; Nguyen K; Yakovenko S; Matthay KK; Weiss WA Neoplasia; 2008 Nov; 10(11):1268-74. PubMed ID: 18953436 [TBL] [Abstract][Full Text] [Related]
19. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas. Huang R; Cheung NK; Vider J; Cheung IY; Gerald WL; Tickoo SK; Holland EC; Blasberg RG FASEB J; 2011 Dec; 25(12):4138-49. PubMed ID: 21856782 [TBL] [Abstract][Full Text] [Related]
20. CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage. Gogolin S; Ehemann V; Becker G; Brueckner LM; Dreidax D; Bannert S; Nolte I; Savelyeva L; Bell E; Westermann F Cell Cycle; 2013 Apr; 12(7):1091-104. PubMed ID: 23462184 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]